|
【结 构 式】 
|
【分子编号】43032 【品名】(2S,3S)-2-[acetyl(methyl)amino]-N-((1S,2S)-1-[[((1S,2R)-2-[[tert-butyl(dimethyl)silyl]oxy]-1-[[((1R)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl)amino]carbonyl]propyl)amino]carbonyl]-2-methylbutyl)-3-methylpentanamide 【CA登记号】 |
【 分 子 式 】C34H64N4O7Si 【 分 子 量 】668.99042 【元素组成】C 61.04% H 9.64% N 8.37% O 16.74% Si 4.2% |
合成路线1
该中间体在本合成路线中的序号：(XV)Alternatively, a solid phase procedure can be followed: Fmoc-Thr(O-TBDMS)-OH (XI) is anchored on 2-chlorotrityl chloride resin by means of DIEA in CH2Cl2 to yield (XII), which then follows a standard solid-phase peptide synthesis (SPPS) protocol to be converted into (XIII). Peptide (XIV) is obtained by treatment of resin (XIII) with HOAc, trifluoroethanol/dichloromethane and is then coupled with intermediate (IX) to afford (XV) in the conditions described above. Finally, the TBDMS group is removed by means of TBAF in THF.
| 【1】 Sin, N.; et al.; Total synthesis of the potent proteasome inhibitor epoxomicin: A useful tool for understanding proteasome biology. Bioorg Med Chem Lett 1999, 9, 15, 2283. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XI),(XII) | 43030 | (2S,3R)-3-[[tert-butyl(dimethyl)silyl]oxy]-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]butyric acid | C25H33NO5Si | 详情 | 详情 | |
| (XIII),(XIV) | 43031 | (2S,3R)-2-[[(2S,3S)-2-([(2S,3S)-2-[acetyl(methyl)amino]-3-methylpentanoyl]amino)-3-methylpentanoyl]amino]-3-[[tert-butyl(dimethyl)silyl]oxy]butyric acid | C25H49N3O6Si | 详情 | 详情 | |
| (IX) | 43028 | tert-butyl ((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)carbamate；tert-butyl (1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butylcarbamate | C14H25NO4 | 详情 | 详情 | |
| (XV) | 43032 | (2S,3S)-2-[acetyl(methyl)amino]-N-((1S,2S)-1-[[((1S,2R)-2-[[tert-butyl(dimethyl)silyl]oxy]-1-[[((1R)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl)amino]carbonyl]propyl)amino]carbonyl]-2-methylbutyl)-3-methylpentanamide | C34H64N4O7Si | 详情 | 详情 |